Introduction {#sec0001}
============

Severe acute respiratory syndrome (SARS-CoV-2), termed as COVID-19 has affected millions of people worldwide. It originated in the city of Wuhan, China and was formally declared as a pandemic by World Health Organization (WHO) on March 11th 2020. It has affected more than five million people and more than 100,000 deaths so far in United States.[@bib0001]

Neurological complications seen in COVD-19 include involvement of both central nervous system (CNS) and peripheral nervous system (PNS). According to a recent study, neurological symptoms were seen in approximately 36% of the patients diagnosed with COVID-19.[@bib0002] Commonly reported CNS symptoms were dizziness, headache, metabolic encephalopathy, taste impairment, smell impairment, vision impairment and neuralgia. Serious neurological complications such as stroke, and seizure, were also reported.[@bib0002] ^,^ [@bib0003] Recent weekly report by centers for disease control and prevention (CDC) reported 0.7% of the US population experienced central nervous system (CNS) complications.[@bib0004]

We share a case series of seven patients, all except one of whom, were Native Americans (NA), and experienced CNS complications during the admission of COVID-19.

Methods {#sec0002}
=======

Retrospective chart review of patients, admitted to University of New Mexico Health Science Center (UNMH) between Feb 01 to April 29, 2020, was done. Patients diagnosed with COVID-19 via reverse transcriptase-polymerase chain reaction (RT-PCR) from nasal swab were screened for development of neurological complications (ischemic stroke, intracerebral hemorrhage, sub-arachnoid hemorrhage, seizure, and encephalitis). Patients with peripheral neurological symptoms such as nerve pain, tingling and/or minor CNS symptoms like headache, mild dizziness, altered mental status without focal neurological signs, or metabolic encephalopathy, were excluded. The study was approved by UNMH institutional review board and was granted a waiver of informed consent ([Fig. 1](#fig0001){ref-type="fig"}, [Fig. 2](#fig0002){ref-type="fig"} ).Fig. 1(Case \# 2): (A) Non-contrast CT- head axial section showing right cerebral hemispheric hypo-attenuation with hemorrhagic transformation (B) Diffusion weighted image (DWI) axial section and (B) Apparent diffusion coefficient (ADC) axial image of post- hemi-craniectomy MRI brain without contrast showing acute ischemic stroke involving right cerebral hemisphereFig 1Fig. 2(Case \# 3): MRI brain without contrast (A) DWI axial image and (B) ADC axial image showing acute infarct in right cerebellar hemisphere. Figure I (Case \# 1): Non-contrast CT head axial sections showing bilateral subarachnoid hemorrhage occupying cerebral sulci. Figure II (Case \# 4): Non-contrast CT head showing right frontal and parietal hypo-attenuation with hemorrhagic transformation extending into bilateral lateral ventricles.Fig 2

Results {#sec0003}
=======

A total of 90 patients with confirmed COVID-19 were screened. Out of 90 patients, 53(59%) were NA, 25(28%) were Caucasian, 4(4%) were African-American and 8(9%) were others. Seven out of ninety (8%) were found to have neurological manifestations including SAH, IPH, IS and seizures, were included. Mean age was 55 years and majority (5 out of 7) were female ***(See*** [Table 1](#tbl0001){ref-type="table"} ***)***. Six patients were Native Americans (NA) and one was Caucasian. All patients presented with symptoms of COVID-19 infection including fever, cough, shortness of breath and general body malaise. Five patients required emergent intubation. All 7 patients required intensive care unit (ICU) level of care.Table 1Clinical characteristics of COVID-19 cases presenting with neurological manifestations.Table 1AgeCase \# 1Case \# 2Case \# 3Case \#4Case \# 5Case \# 6Case \# 7CVASeizuresAge38473958757753GenderFemaleFemaleFemaleFemaleFemaleMaleMaleEthnicityNative AmericanNative AmericanNative AmericanNative AmericanNative AmericanCaucasianNative AmericanBMI55.027.523.524.329.025.322.4Comorbid medical conditionsObesity, Asthma, Anxiety, Depression\
DiabetesAlcohol use disorder in remissionHands and feet birth defect\
DiabetesNo past medical historyHypertension, Diabetes mellitus, complicated ventral hernia repairHypertension, Diabetes Mellitus, hyperlipidemia, Chronic obstructive pulmonary disease, major depressive disorderAlcohol use disorder in remission, traumatic brain injuryHome medicationsIbuprofen, Asthma inhalers, MonteleukastNoneNoneNoneInsulin, Lisinopril, Metformin, AspirinMetformin, Albuterol, Amitryptyline, Aspirin, Pregabalin, Tamsulosin, FurosemideEscitalopram, MultivitaminPresenting vitalsBlood pressure (mmHg)119/74128/6893/86101/7498/76117/64129/78Pulse (bpm)10686106140989982Temperature (°C)36.037.636.137.937.336.436.2O2 sat90%746984936595%COVID-19 presentationFever, cough, Shortness of Breath, chest pain, Chills, MyalgiaFever, Cough,Fever, cough, shortness of breath, chills, fatigueFever, Cough, shortness of breathFever, Abdominal painShortness of breathFeverLabs:WBC (N/L %)10.7 (93/4)10.6 (81/11)20 (N/A)16.2 (N/A)6.8 (54/38)20 (91/3)15.1 (85/8)Platelets263302342239370225227PT/INR (sec/ratio)13.2/1.115.3/1.311.4/1.013.0/1.115.0/1.312.6/1.112.6/1.1ESR (mm/hr)46577.6N/AN/A111N/ACRP17.85.40.4N/AN/A25.4\<0.3LFTsAST:295AST:28AST:22AST:101AST:70AST:148AST:24ALT:86ALT:26ALT:17ALT:75ALT:31ALT:45ALT:15ALP:137ALP:60ALP:219ALP:85ALP:100ALP:129ALP:77TB:0.5TB:1.0TB:0.6TB:0.5TB:0.9TB:0.4TB:1.0TP:8TP:6.8TP:7TP:6.2TP:8.1TP:7TP:6.9AlB:3AlB:2.5AlB:2.5AlB:1.9AlB:2.5AlB:2.1AlB:3.1D-dimer (ng/ml)4211,3802,0611,4251,5351,1131,680Ferritin (ng/ml)397N/AN/AN/AN/AN/AN/AHbA1c (%)7.36.316.85.910.06.6N/ALDL (mg/dl)N/A4635N/A7767N/AHyper-coagulable panel (U/ml)N/AN/APositive anti-cardiolipinN/AN/AN/AN/AVasculitis panel (titre)N/AANA, Anti-DNA positiveN/AN/AN/AN/AN/AEthanol LevelNot detectedNot detectedNot detectedNot doneNot doneNot detectedNot detectedUrine Toxicology screenN/AN/APositive benzodiazepineNot doneNot doneUDM: negPositive oxycodoneChest Imaging Findings:Multifocal pneumoniaMild bibasilar atelectasisMultifocal pneumoniaMultifocal pneumoniaLeft ground glass opacityMultifocal pneumoniaBibasilar atelectasisEmergent Intubation on presentationNoYesYesYesNoYesYesDVT prophylaxis on presentationYesYesYesYesYesYesYesOnset of neurological symptoms from COVID symptomsDay 16Day 6Day 5Day 19Day 7Day 3Day 16Neurological presentationAMS, Not following commands, GCS: 2T1AMS, dilated pupil, GCS: 3T6AMS, Seizures, GCS: 2T6AMS, Fixed pupil, Not following commands, GCS:1T1AMS, SeizureAMS, seizureAMS, Status epilepticusNeuro-imaging findingsNCCTbilateral SAHRight IPH with IVH and SAHNot doneRight large IPH with IVH and SAH with midline shift and herniation.UnremarkableNon- specific right corona radiata calcificationqUnremarkableCTA Head & NeckNot doneNo LVO, AVM or dissectionNo LVO or critical stenosisNot doneNot doneNot doneNot doneMRI brainNot doneRight cerebral hemisphere infarct with HTRight cerebellar hemisphere infarctNot doneNo acute abnormalityNo abnormalityNo AbnormalityMRA or MRV brainNot done *(see supplementary figure 1)*Right sigmoid and transverse sinus thrombosis *(See figure 1)*Not done *(see figure 2)*Not done *(see supplementary figure 2)*Not doneNo sinus venous thrombosis, or critical stenosis, subtel vasogenic edema can be seen with seizuresNot doneVascular territory involved in ischemic stroke-Right Middle Cerebral ArteryLeft Middle Cerebral and Anterior Cerebral ArteryRight Posterior Inferior Cerebellar Artery\-\--EKG findings on admissionSinus tachycardia with non-specific T wave abnormalitiesNormal Sinus rhythm with prolonged Qtc of 495Sinus tachycardia with left axis deviationSinus tachycardia with left axis deviation and low voltage QRS complexesNSR with no specific ST changes unchanged from prior EKGNSR with PVCsNSR with prolonged QTC of 533EEG FindingsNon-epileptiform activityNot doneBurst suppression, no epileptiform activityNot doneNo interictal epileptiform or seizure activityLow amplitude diffuse theta and delta with superimposed beta activityNo epileptiform activityTreatment of neurological diseaseBP controlAnticoagulation, BP control, seizure prophylaxisAntiepileptic, Anticoagulation and high intensity statinAntiplatelet and StatinAntiepileptic and sedationAntiepileptic and sedationAntiepileptic and sedationNeurological interventionNoneEmergent decompressive hemicraniectomy with anterior temporal lobectomy and evacuation of IPHNoneEmergent decompressive hemicraniectomyNoneNoneNoneLength of stay (ICU) (days)19 (17)\
Expired13 (3)\
Discharged SNFN/A\
Still admitted14 (14)\
Expired11 (3)\
Discharged16 (14)\
Discharged6 (2)\
Discharged[^1][^2]

The first four presenting with SAH, IPH, and IS, were NA females with age range 38 -- 58 years. All presented with subjective fevers, shortness of breath and cough. The neurological complication in these four patients was observed between 5-19 days of symptoms onset. Out of other three cases presenting with seizure, two were NA with age range 53-77 years. All three patients required intubation on presentation but two patients required it for seizure and were extubated within 2 days.

All seven patients were on deep venous thrombosis (DVT) prophylaxis with heparin since admission and this was continued appropriately as per clinical needs. None of the patients were treated with therapeutic anticoagulation. Overall length of stay was between 6-19 days and 2-17 days for ICU stay.

Discussion {#sec0004}
==========

To the best of our knowledge, this is the first report sharing neurological complications in NA with COVID-19 infection. Native Americans, who make up less than 2 percent of the U.S. population, comprise 10 % of the population in state of New Mexico. Based on the CDC data, mortality among NA is higher compared to other ethnicities.[@bib0004] In recent reports, it was acknowledged that due to health care disparities and low socioeconomic status, NA were at increased risk of having conditions associated with COVID-19.[@bib0005] Moreover, in general population, NA have a higher incidence of Cerebrovascular accidents (CVA) compared to other ethnic groups.[@bib0006] Approximately 59% of patients managed at our center for COVID-19 infection were NA (51 out of 90) and 6 out of 7 patients with neurological complication were NA. Even though we have a small sample size, our data depicts a higher prevalence of neurological manifestations among NA with COVID-19. We believe that this is due to the known higher prevalence of vascular risk factors such as hypertension, smoking, atrial fibrillation, coronary artery disease, obesity, and alcohol abuse among the NA.[@bib0006]

It is also worth noting that our patients had some unusual findings, especially the presence of IPH. We could not ascertain why our NA patients had a higher incidence of brain bleeds. Klok et al. suggested that patients with severe COVID-19 have higher risk of thromboembolism due to procoagulant state.[@bib0007] Three out of four patients who had CVA, one was found to have venous sinus thrombosis. All of them had elevated d-dimer levels. None of these patients had any atrial arrhythmias or evidence of unstable thrombus or plaques. The ischemic stroke can be partly explained due to pro-thrombotic state with dysregulation of the clotting system secondary to intense inflammation related to cytokine storm leading to thrombus formation.[@bib0008] It might be possible that dysregulation of the clotting cascade might have resulted in hemorrhagic transformation. This same mechanism might be responsible for development of spontaneous SAH, though bleeding at other sites were not observed. None of the patients reported in our study or in prior published manuscripts have had subcortical strokes, which negates accelerated atherosclerosis as the cause of stroke in COVID-19 patients.

The three patients in our case series who experienced seizures had underlying risk factors such as hypertension, diabetes and/or history of alcohol abuse. We hypothesize that development of seizure was a secondary response from the underlying severe systemic illness. For all three patients, any structural lesion, vascular abnormality, metabolic cause, toxin induced or infectious etiology other than COVID-19 infection was ruled out. A recent study from China, demonstrated that SARS-CoV-2 was present in cerebrospinal fluid (CSF) of patients with COVID -19 by genome sequencing.[@bib0009] A recently published case report from Japan did find viral RNA sequencing from CSF and claimed that the patient had meningitis who presented with seizures.[@bib0010] Since most of our patients made clinical recovery with supportive care, further invasive neurological investigation including CSF analyses was not performed, though initial brain imaging and electroencephalogram (EEG) was benign in all three patients.

The understanding of the pathophysiology behind neural involvement in COVID-19 is still in its infancy but various mechanisms have been proposed. Zhao, et al postulated that the virus binds to Angiotensin converting enzyme-2 (ACE2) receptors which are also present in vascular endothelial cells in the brain.[@bib0011] This is one of the potential mechanisms, how viruses can breach the blood brain barrier. Giacomelli et al showed presence of anosmia and dysgeusia as one of the early presenting symptoms suggesting involvement of olfactory and gustatory pathway.[@bib0012] Further investigations are needed to confirm the exact pathophysiology.

Our study has some limitations. It is a single center retrospective study and this data might not be applicable to the general population as the majority of our patients are NA.
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[^1]: Table Legend: AMS: altered mental status, BMI: body mass index, BP: blood pressure, CVA: cerebrovascular accident, HbA1c: Hemoglobin A1c, ICU: intensive care unit, LDL: low density lipoprotein, MRI: magnetic resonance imaging, MRA: magnetic resonance angiogram, NCCT: non-contrast Computed Tomography scan, O~2~ sat: oxygen saturation, P: pulse, PT/INR: prothrombin time/international normalized ratio, T: temperature, WBC: white blood cell count.

[^2]: Reference Ranges: WBC: 4-11 × 10^3^ /µl, Hgb: 12-16 g/dl, Platelet count: 150-400 × 10^3^ /µl, PT: 9.4-15.4 sec, INR: 0.80-1.30, aPTT: 26-38 sec, Anti-DNA: 0-4 IU/ml, D-dimer: 0-500 ng/ml, Fibrinogen: 170-450 mg/dl, TG: \<150 mg/dl, LDL: \<100 mg/dl, HDL: \>40 mg/dl, Cholesterol: \<200 mg/dl, HgbA1c: \>6.5%, Anti-cardiolipin antibodies: 0.0-9.9U/ml, Procalcitonin: \<10ng/ml, Ferritin: 30-530 ng/ml, Platelet count: 150-450k C-Reactive Protein: \<0.3 mg/dl, Erythrocyte Sedimentation Rate:0-28mm/hr, neutrophil E3/uL 1.8-7, lymphocyte 1 -- 3.4 E3/ul, AST 6-58 Unit/Liter, ALT 14-67 Unit/Liter, ALP 38-150 Unit/Liter, Total Bili 0.3-1.2 mg/dl, Total protein 6.1-8.2 g/dl, albumin 3.4-4.7 g/dl.
